Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a
dismal prognosis. While immunotherapy has been deemed a breakthrough treatment for …

Simple Summary There is currently no effective treatment for Pancreatic Ductal
Adenocarcinoma (PDAC), and it is still the deadliest cancer, despite great research efforts in …

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of
malignant and non-malignant disorders. CARs are synthetic transmembrane receptors …

Pancreatic ductal adenocarcinoma (PDAC), a highly malignant neoplasm, is classified as
one of the most severe and devastating types of cancer. PDAC is a notable malignancy that …

Simple Summary Metastatic pancreatic ductal adenocarcinoma has a dismal prognosis, and
to date no curative treatment options exist. The image guided tumor ablation technique …

Pancreatic cancer has a dire prognosis and will represent the second leading cause of
cancer death in the next 10 years. The multifactorial approach represents one of the main …

Background Tumor-specific neoantigens are ideal targets for cancer immunotherapy. As
research findings have proved, neoantigen-specific T cell activity is immunotherapy's most …

Oncogenic Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are highly
prevalent in pancreatic ductal adenocarcinoma (PDAC) and have garnered attention as …

Pancreatic ductal adenocarcinoma (PDAC) is a high fatality cancer with one of the worst
prognoses in solid tumors. Most patients present with late stage, metastatic disease and are …

Objectives To evaluate the efficacy and safety of cytokine-induced killer (CIK) cell therapy in
pancreatic cancer. Methods An orthotopic murine model of pancreatic cancer and adjuvant …